ArticleFrontiers in psychiatry2026
Moxibustion for gastrointestinal cancer-related fatigue: study protocol for a randomized clinical trial.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer-Related Fatigue (CRF) is one of the most prominent subjective symptoms that cancer patients encounter, in particular individuals with gastrointestinal tumors. This fatigue significantly impacts their quality of life, impairs adherence to treatment, and may ultimately reduce overall survival rates. Moxibustion has gradually gained recognition as a therapeutic intervention for CRF. However, clinical evidence supporting the efficacy of moxibustion remains limited. Methods: This investigation employs a randomized, controlled, single-blinded trial design. A 1:1 random allocation method will be implemented to assign 74 participants to either the moxibustion group or the placebo moxibustion group. All participants will undergo eight sessions over 4 weeks, with sessions occurring twice weekly and lasting for 30 minutes each. Assessments for follow-up will take place at week 8. The primary outcome will be the percentage of patients who show a decrease of at least three points on the Brief Fatigue Inventory (BFI) at week 4. Secondary outcomes will encompass changes in the BFI, Quality of Life Questionnaire-Core 30 (QLQ-C30), Generalized Anxiety Disorder Scale-7 (GAD-7). Meanwhile, Blood cell counts and serum T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+) will be measured as exploratory outcomes. In addition, adverse events will be screened and documented throughout the study. An analysis adhering to the intention-to-treat(ITT) principle will be executed. Discussion: This research aims to evaluate the efficacy and safety of moxibustion in patients with gastrointestinal CRF. Additionally, the study seeks to investigate the effects of moxibustion on the immune response in individuals diagnosed with gastrointestinal CRF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.